RNASET2 and hepatocellular carcinoma: Therefore, the UGT1A1 genotype is widely used as a guide for prescribing the appropriate dosage of irinotecan.[47, 48] Additionally, Ou et al. found that knocking down RNASET2 significantly increased the sensitivity of CRC cells to 5‐FU by reducing autophagic uracil production.[23] Based on these findings, we speculate that deficiency in RNASET2, which leads to downregulation of UGT1A1, may also have a significant impact on the effectiveness of targeted therapies in HCC patients, and further investigation in this area is warranted.